Proving an Unparalleled Commitment to Human Subject Protection

Univo IRB, today’s fastest-growing central institutional review board (IRB), announced it has successfully completed a routine inspection by the U.S. Food and Drug Administration (FDA) with no findings. The outcome exemplifies Univo IRB’s unwavering commitment to protecting research participants and upholding the highest standards of ethical and regulatory oversight in clinical research.

“This inspection result reflects our expertise, diligence, and continued focus on strong processes, rigorous review, and responsible oversight, because there is nothing more important than patient protection,” said Cyrus Gill, Executive IRB Chair of Univo IRB.

Since its launch, Univo IRB has provided hundreds of sponsors, CROs, research sites, and institutions with an alternative central IRB solution — one that brings a trusted solution through transparency, responsiveness, and quality at scale to CROs, large pharma, biotechs, sites, and individual investigators alike.

Univo IRB’s industry veterans bring deep experience across clinical trial operations, research ethics, regulatory compliance, and patient experience. The organization also uses its industry-leading, purpose-built and proprietary technology, OneVerse^®, to enhance their work revolutionizing protocol review, human research protections, and ongoing study oversight.

“This milestone affirms the strength of our quality systems and human research protection expertise brought to every study we review,” added Julie Blasingim, Chief Executive Officer of Univo IRB. “We remain dedicated to delivering a trusted service built on principles of compliance and patient voice while redefining human research protections for today’s research.”

About Univo IRB

Univo IRB provides independent ethics review and oversight for clinical research to help ensure participant protection and compliance with applicable regulations and guidelines. Univo IRB’s experts are revolutionizing the IRB industry with industry-leading modern technology, a focus on customer experience, and a firm commitment to the voice of the patient.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113845193/en/